Cargando…

Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma

INTRODUCTION: Subspecies of apolipoproteins can be defined by fractionating apolipoproteins based on the presence and absence of coexisting apolipoproteins. METHODS: We determined age- and sex-adjusted correlations of enzyme-linked immunosorbent assay–measured plasma and cerebrospinal fluid (CSF) ap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koch, Manja, Furtado, Jeremy D., Falk, Kim, Leypoldt, Frank, Mukamal, Kenneth J., Jensen, Majken K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	CSF Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338868/ https://www.ncbi.nlm.nih.gov/pubmed/28289700 http://dx.doi.org/10.1016/j.dadm.2017.01.007

Ejemplares similares

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

Cerebrospinal fluid collection: An informative animation video for patients and caregivers
por: Babapour Mofrad, R., et al.
Publicado: (2019)

Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia
por: Forlenza, Orestes V., et al.
Publicado: (2015)

Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics
por: Teunissen, Charlotte E., et al.
Publicado: (2016)

Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study
por: Leung, Yuk Yee, et al.
Publicado: (2015)

Cerebrospinal fluid ratios with Aβ(42) predict preclinical brain β-amyloid accumulation
por: Racine, Annie M., et al.
Publicado: (2015)

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease
por: Kruse, Niels, et al.
Publicado: (2018)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios
por: Marelli, Cecilia, et al.
Publicado: (2015)

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?
por: Paterson, Ross W., et al.
Publicado: (2015)

Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ(1-42), T-tau, and P-tau values
por: Willemse, Eline A.J., et al.
Publicado: (2017)

Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project
por: Willemse, Eline A.J., et al.
Publicado: (2018)

Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants
por: Li, Wei, et al.
Publicado: (2017)

A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging
por: Mo, Yi, et al.
Publicado: (2017)

Apolipoproteins and Alzheimer's pathophysiology
por: Koch, Manja, et al.
Publicado: (2018)

CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume
por: Düzel, Emrah, et al.
Publicado: (2018)

Consensus guidelines for lumbar puncture in patients with neurological diseases
por: Engelborghs, Sebastiaan, et al.
Publicado: (2017)

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease
por: Dekker, Alain D., et al.
Publicado: (2017)

Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios
por: Toombs, Jamie, et al.
Publicado: (2018)

Derivation of cutoffs for the Elecsys(®) amyloid β (1–42) assay in Alzheimer's disease
por: Shaw, Leslie M., et al.
Publicado: (2018)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Lumbar puncture in patients with neurologic conditions
por: Babapour Mofrad, Rosha, et al.
Publicado: (2017)

Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ(42/40) ratio
por: Pouclet-Courtemanche, Hélène, et al.
Publicado: (2019)

Association of Apolipoprotein E in Lipoprotein Subspecies With Risk of Dementia
por: Koch, Manja, et al.
Publicado: (2020)

High‐Density Lipoprotein Subspecies Defined by Apolipoprotein C‐III and Subclinical Atherosclerosis Measures: MESA (The Multi‐Ethnic Study of Atherosclerosis)
por: Aroner, Sarah A., et al.
Publicado: (2018)

Quantification of the Light Subunit of Neurofilament Protein in Cerebrospinal Fluid of Huntington’s Disease Patients
por: Szejko, Natalia, et al.
Publicado: (2018)

Complications of external cerebrospinal fluid drainage in aneurysmal subarachnoid haemorrhage
por: Arts, Sebastian, et al.
Publicado: (2021)

Cerebrospinal fluid dynamics in idiopathic intracranial hypertension: a literature review and validation of contemporary findings
por: Kaipainen, Aku L, et al.
Publicado: (2021)

Associations of HDL Subspecies Defined by ApoC3 with Non-Alcoholic Fatty Liver Disease: The Multi-Ethnic Study of Atherosclerosis
por: Morze, Jakub, et al.
Publicado: (2020)

Cerebrospinal fluid and venous biomarkers of shunt-responsive idiopathic normal pressure hydrocephalus: a systematic review and meta-analysis
por: Thavarajasingam, Santhosh G., et al.
Publicado: (2022)

Plasma antioxidants and risk of dementia in older adults
por: Koch, Manja, et al.
Publicado: (2021)

Compliance of the cerebrospinal space: comparison of three methods
por: Kazimierska, Agnieszka, et al.
Publicado: (2021)

Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
por: Bader, Jakob M, et al.
Publicado: (2020)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?
por: Del Campo Milan, Marta, et al.
Publicado: (2015)

Cerebrospinal fluid irisin correlates with amyloid‐β, BDNF, and cognition in Alzheimer's disease
por: Lourenco, Mychael V., et al.
Publicado: (2020)

Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease
por: Dhiman, Kunal, et al.
Publicado: (2020)

Measurement batch differences and between‐batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values
por: Ma, Yue, et al.
Publicado: (2021)

Redox index of Cys-thiol residues of serum apolipoprotein E and its diagnostic potential
por: Yamauchi, Kazuyoshi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_udepfhcku1jum45p0i0aqcqofm